Don't need to look far. Another ASX listed company also founded and chaired by PH is Chimeric Therapeutics (CHM).
They have had some success in treating glioblastoma (an aggressive brain tumour) with CAR-T therapy and have started a clinical trial in gastrointestinal tumours utilising another CAR-T.
But there are hundreds of different CAR-T/NK/other immune cells under development for solid tumours.
Imugene's advantage with onCARlytics would be potentially allowing already approved CD19 CAR-Ts and bispecifics to be directed to solid tumours, and hopefully a wide range of solid tumours. Add in an allogenic CAR-T like Azer-Cel and the treatment becomes truely off-the-shelf.
Don't need to look far. Another ASX listed company also...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
-0.001(2.50%) |
Mkt cap ! $290.0M | |||
| Open | High | Low | Value | Volume |
| 4.0¢ | 4.1¢ | 3.9¢ | $277.0K | 7.071M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 3134882 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.0¢ | 975000 | 5 |
View Market Depth
| Last trade - 16.10pm 13/12/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
